Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$0.87 USD
-0.01 (-1.14%)
Updated Sep 19, 2024 10:40 AM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Predictive Oncology Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 22 | 28 | 1 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 0 | 0 |
Total Current Assets | 10 | 23 | 29 | 2 | 1 |
Net Property & Equipment | 1 | 2 | 3 | 4 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 11 | 6 | 19 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 26 | 44 | 13 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 4 | 5 |
Accounts Payable | 1 | 1 | 1 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 1 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 3 | 9 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 4 | 4 | 10 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 1 | 1 | 0 | 0 |
Capital Surplus | 176 | 175 | 168 | 111 | 94 |
Retained Earnings | -168 | -154 | -128 | -108 | -83 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 8 | 22 | 40 | 3 | 11 |
Total Liabilities & Shareholder's Equity | 14 | 26 | 44 | 13 | 22 |
Total Common Equity | 8 | 22 | 40 | 3 | 11 |
Shares Outstanding | 4.00 | 3.90 | 3.20 | 0.90 | 0.20 |
Book Value Per Share | 2.07 | 5.58 | 12.58 | 2.93 | 55.95 |
Fiscal Year End for Predictive Oncology Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 5 | 9 | 12 | 15 |
Receivables | 0 | 1 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 0 | 1 | 1 | 0 |
Total Current Assets | 7 | 7 | 10 | 14 | 16 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 11 | 11 | 14 | 18 | 21 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 2 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Total Current Liabilities | 5 | 5 | 4 | 4 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 7 | 6 | 7 | 6 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 179 | 176 | 176 | 176 | 176 |
Retained Earnings | -175 | -172 | -168 | -164 | -161 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 4 | 8 | 12 | 15 |
Total Liabilities & Shareholder's Equity | 11 | 11 | 14 | 18 | 21 |
Total Common Equity | 4 | 4 | 8 | 12 | 15 |
Shares Outstanding | 5.70 | 4.00 | 4.00 | 4.00 | 3.90 |
Book Value Per Share | 0.72 | 1.01 | 2.07 | 2.91 | 3.77 |